Advertisement

Issue 25, Volume 128

Cover Figure: Highly efficient xenograft mouse model for human leukemia.  See the article by Antonelli al.

WASHINGTON, December 22, 2016 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma
Dejoie et al demonstrate the superiority of serum over urine free light chain testing in the measurement of response in light chain multiple myeloma, providing improved accuracy, sensitivity, and prognostic value.

Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches
Antonelli et al developed a novel xenograft mouse model that mimics a humanized bone marrow niche that improves human leukemia cell engraftment and promotes growth and clonal diversity.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype
Basiorka et al challenge how we think about cell death in myelodysplastic syndromes (MDSs). They furnish an explanation for the shared morphologic alterations that are seen in spite of the marked genetic heterogeneity, and they identify a new target for therapeutic intervention.

Atorvastatin enhances endothelial cell function in posttransplant poor graft function
Shi et al report on the functional deficits of marrow endothelial progenitor cells (EPCs) in patients with poor graft function after allogenic stem cell transplantation that can be improved in vitro with atorvastatin exposure.

Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation
Aljitawi et al demonstrate for the first time that erythropoietin (EPO) signaling directly inhibits hematopoietic stem and progenitor cell migration and show that an acute and transient reduction in peripheral EPO levels just before transplant can enhance hematopoietic engraftment after umbilical cord blood transplantation.

Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies
The authors review data on a less-utilized target for the treatment of B-cell malignancies, phosphodiesterase 4 (PDE4), and in light of the anti-inflammatory/immunomodulatory activity of PDE4 inhibitors, they present a rationale for their therapeutic use.

How I treat anticoagulation in atrial fibrillation
In this How I Treat paper, Steinberg discusses anticoagulation treatment options for stroke prevention in patients with nonvalvular atrial fibrillation.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT
The management of relapsed chronic lymphocytic leukemia (CLL) post­­–allogeneic transplant is challenging. The authors provide clinical and immunologic data suggesting that treatment of these patients with ibrutinib is highly effective.

Basophil tryptase mMCP-11 plays a crucial role in IgE-mediated, delayed-onset allergic inflammation in mice
This work provides the first demonstration that the basophil-derived mouse mast cell protease-11 (mMCP-11) contributes to immunoglobulin E–mediated chronic allergic inflammation in mice.

A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis
Patients with chorea-acanthocytosis often present with spiculated red blood cells. This work associates this abnormality with heightened Lyn kinase activity and dysregulated features of autophagy.

The American Society of Hematology Clinical Research Training Institute is associated with high retention in academic hematology
The evaluation of the American Society of Hematology (ASH) Clinical Research Training Institute (CTRI) shows that the program is well received and it is associated with an increased retention of academic hematologists who demonstrate increased, continued participation in patient-oriented research.

 

This week's complete table of contents

Why Submit to Blood?

 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.